A practical reference on LC-MS/MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-19 and is reviewed periodically as new material appears.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
==== Natural gas ==== Commonly, HIC of natural gas from the same well has a trend of δDmethane < δDethane < δDpropane < δDC4+. This is because most natural gas is thought to be generated by stepwise thermal cracking that is mostly irreversible and thus governed by normal kinetic isotope effects (KIE) that favor light isotopes. The same trend, known as "the normal order", holds for carbon isotopes in natural gas. For example, Angola gas reportedly has a methane δD range of −190‰ to −140‰, an ethane δD of −146‰ to −107‰, a propane δD of −116‰ to −90‰, and a butane δD of −118‰ to −85‰. However, some recent studies show that opposite patterns could also exist, meaning δDmethane > δDethane > δDpropane. This phenomenon is often called 'isotopic reversal' or 'isotopic rollover'. The isotopic order could also be partly reversed, like δDmethane > δDethane < δDpropane or δDmethane < δDethane > δDpropane. Burruss et al. found that in the deepest samples of northern Appalachian basin the hydrogen isotopic order for methane and ethane is reversed. Liu et al., also found partial reversal in oil-related gas from the Tarim Basin. The mechanism causing this reversal is still unknown. Possible explanations include mixing between gases of different maturities and sources, oxidation of methane, etc. Jon Telling et al., synthesized isotopically reversed (in both C and H) low-molecular alkanes using gas-phase radical recombination reactions in electrical discharge experiments, providing another possible mechanism. Methane is the main component of natural gas.
=== Commercial synthesis === The starting material is either the amino acid alanine, or propionic acid converted into alanine via halogenation and amination. Then, the procedure accomplishes the conversion of the amino acid into pyridoxine through the formation of an oxazole intermediate followed by a Diels–Alder reaction, with the entire process referred to as the "oxazole method". The product used in dietary supplements and food fortification is pyridoxine hydrochloride, the chemically stable hydrochloride salt of pyridoxine. Pyridoxine is converted in the liver into the metabolically active coenzyme form pyridoxal 5'-phosphate. At present, while the industry mainly utilizes the oxazole method, there is research exploring means of using less toxic and dangerous reagents in the process. Fermentative bacterial biosynthesis methods are also being explored, but are not yet scaled up for commercial production.
As ultra-high-definition broadcasts at full resolution are designed for large, wall-sized displays, there is a possibility that fast-moving subjects may not be clear when shot at 60 fps, so the option of 120 fps has been standardized for these situations. To handle the sensor output of approximately 4 billion pixels per second with a data rate as high as 51.2 Gbit/s, a faster analog-to-digital converter has been developed to process the data from the pixels, and then a high-speed output circuit distributes the resulting digital signals into 96 parallel channels. This 1.5 in (38 mm) CMOS sensor is smaller and uses less power when compared to conventional ultra-high-definition sensors, and it is also the world's first to support the full specifications of the ultra-high-definition standard. During the 2012 Summer Olympics in Great Britain, the format was publicly showcased by the world's largest broadcaster, the BBC, which set up 15-meter-wide screens in London, Glasgow, and Bradford to allow viewers to see the Games in ultra-high definition. On May 31, 2012, Sony released the VPL-VW1000ES 4K 3D Projector, the world's first consumer-prosumer projector using the 4K UHDTV system, with the shutter-glasses stereoscopic 3D technology priced at US$24,999.99. On August 22, 2012, LG announced the world's first 3D UHDTV using the 4K system. On August 23, 2012, UHDTV was officially approved as a standard by the International Telecommunication Union (ITU), standardizing both 4K and 8K resolutions for the format in ITU-R Recommendation BT.2020.
==== Metabolism ==== Ramelteon is metabolized in the liver primarily by oxidation via hydroxylation and carbonylation. It is also secondarily metabolized to produce glucuronide conjugates. Ramelteon is metabolized mainly by CYP1A2 while CYP2C enzymes and CYP3A4 are involved to a minor extent. The metabolites of ramelteon include M-I, M-II, M-III, and M-IV. Exposure to M-II is approximately 20- to 100-fold higher than to ramelteon.
Sources: en.wikipedia.org
Moreover, the importance of siRNA and the innate immune system is to include more PRRs to help recognize different RNA structures. This makes it more likely for the siRNA to cause an immunostimulant response in the event of the pathogen.
=== Diabetes === Heart disease is twice as common in people with diabetes. In diabetics, cardiovascular complications occur at an earlier age and often result in premature death, making heart disease the major killer of diabetic people. Cardiolipin has been found to be deficient in the heart at the earliest stages of diabetes, possibly due to a lipid-digesting enzyme that becomes more active in diabetic heart muscle.
=== Energy === In July 2018, Minister Rickford tabled Bill 2: Urgent Priorities Act, which received Royal Assent in the same month. The first session of the 42nd Legislature was on July 11 and Bill 2, which passed into law on July 25, was the Ford Government's first piece of legislation. Bill 2—an omnibus bill—was "criticized by both "business groups and unions". It legislated an end to the strike between York University and Canadian Union of Public Employees (CUPE), cancelled the White Pines Wind Project wind farm contract, and gave Ontario government "veto power over compensation at Hydro One." In December 2025, Ford and New York governor Kathy Hochul signed a memorandum of understanding which makes the New York Power Authority and Ontario Power Generation work together on advancing nuclear energy technology. In July 2026, Ford and Alberta premier Danielle Smith proposed an oil pipeline from Alberta to Sarnia, Ontario.
Acting as a pro-apoptotic protein in many contexts, the normal levels of this protein mean that, in most cases, the initiated cell-death signaling pathways have an influence on the mitochondrial apoptosis pathway. This protein can have a premature prolonged apoptotic response with the risk of having not enough galectin-7 to re-epithelialize, delaying wound repair and skin closure through skin cell migration. This can be seen in aged skin which is considered to be a potential reason why wound repair is delayed in older individuals who would have less of this protein in them. With varying roles depending on the cellular conditions and factors, the protein is researched under induced ectopic expression in cancerous conditions. The discovered association between apoptosis and an over expression of galectin-7 has been found in apoptotic keratinocytes. The possible issue of the process of re-epithelialization being compromised or delayed would result in painful and serious wound disorders that would be difficult to treat as it has already affected the human tissue. The dangers of failure of re-epithelialization causes concern for uncontrolled inflammation, especially in the intestinal tract, and other immune responses that are more general. The cause for this isn't so much the inability for cell proliferation but instead the potential for the epithelium to migrate across the bed of the wound decreasing.
The General Principles of Software Validation (FDA 2002) defines verification as "Software verification provides objective evidence that the design outputs of a particular phase of the software development life cycle meet all of the specified requirements for that phase." It also defines Validation as "Confirmation by examination and provision of objective evidence that software specifications conform to user needs and intended uses, and that the particular requirements implemented through software can be consistently fulfilled". The software validation guideline states: “The software development process should be sufficiently well planned, controlled, and documented to detect and correct unexpected results from software changes." Annex 11 states "The validation documentation and reports should cover the relevant steps of the life cycle." Weichel (2004) recently found that over twenty warning letters issued by the FDA to pharmaceutical companies specifically cited problems in Computer System Validation between 1997 and 2001. Probably the best known industry guidance available is the GAMP Guide, now in its fifth edition and known as GAMP5 published by ISPE (2008). This guidance gives practical advice on how to satisfy regulatory requirements.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.